Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Neutropenia: a condition in which the body has a low ... therapy — which is already approved in the U.S. — for adults with lower-risk myelodysplastic syndromes who have anemia requiring frequent red ...

Neutropenia may result from chemotherapy (common in leukemia treatment), bone marrow disorders like aplastic anaemia or myelodysplastic syndromes, infections, or side effects of certain medications.

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS ... points to a high risk of neutropenia and thrombocytopenia ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

Telangana: Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the ...

Patients' clinical records and data were collected by members of the research team, data collected included age, sex, pre-transplant ferritin level, platelet engraftment time, neutrophil engraftment .

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients ...